ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Daito Pharmaceutical Co., Ltd. ?
1
High Management Efficiency with a high ROE of 7.40%
2
Company has very low debt and has enough cash to service the debt requirements
3
Poor long term growth as Net Sales has grown by an annual rate of 1.39% and Operating profit at -14.40% over the last 5 years
4
With a growth in Net Profit of 235.28%, the company declared Outstanding results in Feb 26
- INVENTORY TURNOVER RATIO(HY) Highest at 2.12 times
- INTEREST COVERAGE RATIO(Q) Highest at 6,875.76
- RAW MATERIAL COST(Y) Fallen by -23.57% (YoY)
5
With ROE of 4.39%, it has a very attractive valuation with a 0.86 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 13.43%, its profits have fallen by -3.4%
6
Underperformed the market in the last 1 year
- The stock has generated a return of 13.43% in the last 1 year, much lower than market (Japan Nikkei 225) returns of 69.64%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Daito Pharmaceutical Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Daito Pharmaceutical Co., Ltd. for you?
Low Risk, Low Return
Absolute
Risk Adjusted
Volatility
Daito Pharmaceutical Co., Ltd.
-100.0%
0.04
21.63%
Japan Nikkei 225
71.75%
2.62
26.55%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
1.39%
EBIT Growth (5y)
-14.40%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0.37
Net Debt to Equity (avg)
0.15
Sales to Capital Employed (avg)
0.79
Tax Ratio
40.30%
Dividend Payout Ratio
55.80%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
9.93%
ROE (avg)
7.40%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
20
Industry P/E
Price to Book Value
0.86
EV to EBIT
18.48
EV to EBITDA
7.19
EV to Capital Employed
0.88
EV to Sales
1.00
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
4.75%
ROE (Latest)
4.39%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend23What is working for the Company
INVENTORY TURNOVER RATIO(HY)
Highest at 2.12 times
INTEREST COVERAGE RATIO(Q)
Highest at 6,875.76
RAW MATERIAL COST(Y)
Fallen by -23.57% (YoY
DEBTORS TURNOVER RATIO(HY)
Highest at 3 times
OPERATING PROFIT(Q)
Highest at JPY 2,269 MM
OPERATING PROFIT MARGIN(Q)
Highest at 19.58 %
PRE-TAX PROFIT(Q)
Highest at JPY 1,435 MM
NET PROFIT(Q)
Highest at JPY 1,036 MM
EPS(Q)
Highest at JPY 35.2
-5What is not working for the Company
INTEREST(9M)
At JPY 96 MM has Grown at 12.94%
CASH AND EQV(HY)
Lowest at JPY 4,095 MM
NET SALES(Q)
Lowest at JPY 11,591 MM
Here's what is working for Daito Pharmaceutical Co., Ltd.
Pre-Tax Profit
At JPY 1,435 MM has Grown at 257.86%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (JPY MM)
Net Profit
At JPY 1,036 MM has Grown at 374.24%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very positive
Net Profit (JPY MM)
Interest Coverage Ratio
Highest at 6,875.76
in the last five periodsMOJO Watch
The company's ability to manage interest payments is improving
Operating Profit to Interest
Inventory Turnover Ratio
Highest at 2.12 times and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Operating Profit
Highest at JPY 2,269 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (JPY MM)
Operating Profit Margin
Highest at 19.58 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at JPY 1,435 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (JPY MM)
Net Profit
Highest at JPY 1,036 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (JPY MM)
EPS
Highest at JPY 35.2
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (JPY)
Debtors Turnover Ratio
Highest at 3 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -23.57% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Depreciation
Highest at JPY 1,143 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (JPY MM)
Here's what is not working for Daito Pharmaceutical Co., Ltd.
Interest
At JPY 96 MM has Grown at 12.94%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (JPY MM)
Net Sales
Lowest at JPY 11,591 MM
in the last five periodsMOJO Watch
Near term sales trend is negative
Net Sales (JPY MM)
Cash and Eqv
Lowest at JPY 4,095 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
